Senior​/Principal Scientist, Bioinformatics

About Acrivon Therapeutics, Inc.

Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome.

These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors.

The Phase 1/2 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development.

In addition, the company is advancing ACR-6840 and other potential development candidates targeting CDK
11.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

The Senior Scientist/Principal Scientist, Bioinformatics, within the Data Science team will play a central role in developing and applying advanced computational approaches to support drug discovery and development, leveraging Acrivon’s generative phosphoproteomics AP3 platform. We are seeking a highly accomplished scientist with expertise in building scalable analytical workflows, applying rigorous quantitative methods, and extracting actionable biological insights from large-scale omics data.

The successful candidate will lead analyses across proteomics, phosphoproteomics, transcriptomics, and other high-dimensional datasets, integrating these data with systems biology and AI/ML approaches to inform target discovery, mechanism-of-action studies, indication selection, and biomarker identification. Experience in proteomics-driven pathway analysis and network biology will be highly valued. This individual will work closely within a multidisciplinary environment that includes proteomics, biology, and biomarker teams to maximize the scientific and translational value of Acrivon’s AP3 platform.

This role is based in Watertown, MA.

• Lead computational analysis and interpretation of large-scale proteomics and other multi-omics datasets to support mechanism-of-action studies, indication prioritization, target identification and validation, and biomarker discovery.
• Design, develop, and optimize robust, scalable, and secure computational pipelines for proteomics and multi-omics data analysis.
• Develop and maintain interactive web-based applications and data visualization tools that enable robust analytics within a cloud-based environment.
• Evaluate and incorporate emerging bioinformatics, mass spectrometry proteomics, and AI/ML technologies into data…